{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T08:20:08Z","timestamp":1787818808743,"version":"build-2784847793"},"reference-count":8,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Charlie\u2019s Foundation for Research"},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"DOI":"10.1093\/ajrccm\/aamag352","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T11:45:50Z","timestamp":1782992750000},"page":"1897-1898","source":"Crossref","is-referenced-by-count":0,"title":["One elevated blood eosinophil count is enough to identify mepolizumab responders in chronic obstructive pulmonary disease"],"prefix":"10.1093","volume":"212","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3003-7918","authenticated-orcid":false,"given":"Sanjay","family":"Ramakrishnan","sequence":"first","affiliation":[{"name":"Institute for Respiratory Health, University of Western Australia , Perth,","place":["Australia"]},{"name":"Department of Respiratory Medicine, Sir Charles Gairdner Hospital , Perth,","place":["Australia"]},{"name":"UWA Medical School, University of Western Australia , Perth,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"2026082704020889600_aamag352-B1","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1056\/NEJMoa1708208","article-title":"Mepolizumab for eosinophilic chronic obstructive pulmonary disease","volume":"377","author":"Pavord","year":"2017","journal-title":"N Engl J Med"},{"key":"2026082704020889600_aamag352-B2","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1056\/NEJMoa2413181","article-title":"Mepolizumab to prevent exacerbations of COPD with an eosinophilic phenotype","volume":"392","author":"Sciurba","year":"2025","journal-title":"N Engl J Med"},{"key":"2026082704020889600_aamag352-B3","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1093\/ajrccm\/aamag040","article-title":"Monoclonal antibody therapy in COPD: will it prevent hospitalisations?","volume":"212","author":"Lam","year":"2026","journal-title":"Am J Respir Crit Care Med"},{"key":"2026082704020889600_aamag352-B4","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1093\/ajrccm\/aamag288","article-title":"Mepolizumab efficacy in COPD: insights from longitudinal patterns of blood eosinophil counts and their variability across three clinical trials","volume":"212","author":"Criner","year":"2026","journal-title":"Am J Respir Crit Care Med"},{"key":"2026082704020889600_aamag352-B5","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.chest.2026.02.005","article-title":"Win ratio analysis to clarify clinical benefits: a post hoc analysis of phase 3 BOREAS and NOTUS","volume":"170","author":"Ramakrishnan","year":"2026","journal-title":"Chest"},{"key":"2026082704020889600_aamag352-B6","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1093\/ajrccm\/aamag292","article-title":"Defining disease stability in COPD: evidence from phase 3 clinical trials","volume":"212","author":"Singh","year":"2026","journal-title":"Am J Respir Crit Care Med"},{"key":"2026082704020889600_aamag352-B7","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1164\/rccm.202407-1287RL","article-title":"Blood eosinophil count stability in chronic obstructive pulmonary disease and the eosinophilic exacerbator phenotype","volume":"211","author":"Baraldi","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"2026082704020889600_aamag352-B8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S2213-2600(24)00299-6","article-title":"Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial","volume":"13","author":"Ramakrishnan","year":"2025","journal-title":"Lancet Respir Med"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/212\/9\/1897\/70808979\/aamag352.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/212\/9\/1897\/70808979\/aamag352.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T08:02:14Z","timestamp":1787817734000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/212\/9\/1897\/8724501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":8,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,7,3]]},"published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ajrccm\/aamag352","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,7,3]]}}}